BioMarin price target raised to $110 from $100 at Wells Fargo

Wells Fargo raised the firm’s price target on BioMarin to $110 from $100 and keeps an Overweight rating on the shares. Other than Roctavian number, there were a lot of positives from the Q1 call, which set up BioMarin as a good long-term investment, the firm says. In the short term, Wells thinks upcoming investor day is a key catalyst, which could provide color on margins and direction.